

#### Disclaimer

This English translation is prepared by Marketing Authorization Holder.

The Japanese language package insert is the official document, and this translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version prevails.

The provider of this translation shall not be responsible for any damage that may be attributed to the use of the translation.

This translation shall not be reproduced, reprinted or used for profit.

Since this translation is prepared in July 2025 based on the Japanese text current at that time, the translation may not reflect the latest information, due to continuous revision of package inserts.

The latest Japanese text is available on PMDA website.

# Kracie

Oct 2023 (1st version)

Standard Commodity Classification No. of Japan
--

875200

Approval No.
--------------

21900AMX00622000

Date of Initial Marketing in Japan
------------------------------------

Oct 1986

Kampo product

## Kracie Shimpito Extract Fine Granules

Storage : Store at room

temperature

Shelf Life : 3 years

KB-85

EK-85

### 3. COMPOSITION AND PRODUCT DESCRIPTION

#### 3.1 Composition

Brand name	Kracie Shimpito Extract Fine Granules	
Active ingredients	The daily dose of this product (6.0 g) contains 3,000 mg of Shimpito extract powder, derived from a mixture of the following crude drugs.	
	JP Citrus Unshiu Peel	3.0 g
	JP Perilla Herb	3.0 g
	JP Bupleurum Root	4.0 g
	JP Ephedra Herb	3.0 g
	JP Glycyrrhiza	2.0 g
	JP Magnolia Bark	3.0 g
	JP Apricot Kernel	4.0 g
Inactive ingredients	JP Magnesium Stearate, JP Microcrystalline Cellulose, JP Lactose Hydrate, Hydrated Silicon Dioxide	

(JP: The Japanese Pharmacopoeia)

#### 3.2 Product Description

Dosage form	Fine granules
Color	Light brown to brown
Odor	Practically none or slightly characteristic odor
Taste	Slightly sweet, bitter afterwards
ID code	KB-85 (3.0 g per sachet)
	EK-85 (2.0 g per sachet)

### 4. INDICATIONS

**Childhood asthma, bronchial asthma, bronchitis**

### 6. DOSAGE AND ADMINISTRATION

The usual adult dosage for oral use is 6.0 g daily in two or three divided doses before or between meals.

The dosage may be adjusted according to the patient's age, body weight, and symptoms.

### 8. IMPORTANT PRECAUTIONS

**8.1** When this product is used, the patient's "SHO"

(constitution/symptoms) should be taken into consideration.

The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

**8.2** Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc. [See Sections 10.2, 11.1.1, 11.1.2.]

**8.3** When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs.

### 9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS

**9.1 Patients with Complication or History of Diseases, etc.**

**9.1.1 Patients in a period of weakness after disease or with extremely weakened constitution**

Adverse reactions are likely to occur, and the symptoms may be aggravated.

**9.1.2 Patients with an extremely weak gastrointestinal tract**

Anorexia, epigastric distress, nausea, vomiting, etc. may occur.

**9.1.3 Patients with anorexia, nausea, or vomiting**

These symptoms may be aggravated.

**9.1.4 Patients with a significant sweating tendency**

Excessive sweating, systemic weakness, etc. may occur.

**9.1.5 Patients with cardiovascular disorders, including angina pectoris or myocardial infarction, or patients with a history of such disorders**

The disease and its symptoms may be aggravated.

**9.1.6 Patients with severe hypertension**

The disease and its symptoms may be aggravated.

**9.1.7 Patients with urination impaired**

The disease and its symptoms may be aggravated.

**9.1.8 Patients with hyperthyroidism**

The disease and its symptoms may be aggravated.

**9.2 Patients with Renal Impairment**

**9.2.1 Patients with severe renal disorder**

The disease and its symptoms may be aggravated.

**9.5 Pregnant Women**

This product should be used in pregnant women or women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

**9.6 Breast-feeding Women**

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered.

**9.7 Pediatric Use**

No clinical studies have been conducted in children.

**9.8 Geriatric Use**

Since the physiological functions are generally decreased in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

## 10. INTERACTIONS

### 10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Ephedra Herb-containing preparations Kakkonto Shoseiryuto Maoto, etc. Ephedrine-containing preparations Ephedrine Hydrochloride dl-Methyl Ephedrine Hydrochloride Fexofenadine Hydrochloride/Pseudoephedrine Hydrochloride, etc. Monoamine Oxidase (MAO) inhibitors Selegiline Hydrochloride Rasagiline Mesilate, etc. Thyroid gland preparations Thyroxine Liothyronine, etc. Catecholamine preparations Adrenaline Isoprenaline, etc. Xanthine preparations Theophylline Diprophylline, etc.	Since insomnia, excessive sweating, tachycardia, palpitation, systemic weakness, mental excitement, etc. are likely to occur, this product should be administered with care by reducing the dosage, etc.	The sympathomimetic effect may be enhanced.
Glycyrrhiza-containing preparations Shakuyakukanzoto Hochuekkito Yokukansan, etc. Preparations containing glycyrrhizic acid and its salts Monoammonium Glycyrrhizinate/Glycine/L-cysteine Monoammonium Glycyrrhizinate/Glycine/DL-Methionine combination tablets, etc. [See Sections 8.2, 11.1.1, 11.1.2]	Pseudoaldosteronism is likely to occur. As a result of hypokalaemia, myopathy is likely to occur.	Since glycyrrhizic acid has an accelerating effect on potassium excretion in the renal tubules, an acceleration of decrease in the serum potassium level has been suggested.

## 11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

### 11.1 Clinically Significant Adverse Reactions

#### 11.1.1 Pseudoaldosteronism (frequency unknown)

Pseudoaldosteronism such as hypokalaemia, blood pressure increased, retention of sodium/body fluid, edema, and body weight gain may occur. Patients should be carefully monitored (e.g., measurement of serum potassium levels), and if any abnormalities are observed, administration should be discontinued, and appropriate measures such as administration of potassium preparations should be taken. [See Sections 8.2, 10.2]

#### 11.1.2 Myopathy (frequency unknown)

Myopathy may occur as a result of hypokalaemia. Patients should be carefully monitored, and if any abnormalities such as feelings of weakness, muscle cramp in extremities, or paralysis are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken. [See Sections 8.2, 10.2]

### 11.2 Other Adverse Reactions

	Frequency unknown
Autonomic	Insomnia, Excessive sweating, Tachycardia, Palpitations, Systemic weakness, Mental excitement, etc.
Gastrointestinal	Anorexia, Epigastric distress, Nausea, Vomiting, etc.
Urinary	Urination impaired, etc.

## 20. PRECAUTIONS FOR HANDLING

**20.1** To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.

**20.2** Avoid moisture, especially after opening, and handle with care.

**20.3** Since this product is made from crude drugs, the color of the product may vary.

## 22. PACKAGING

(KB-85)

3.0 g × 28 packets [sachets]

3.0 g × 168 packets [sachets]

(EK-85)

2.0 g × 42 packets [sachets]

2.0 g × 294 packets [sachets]

500 g [bottle]

## 26. MARKETING AUTHORIZATION HOLDER, etc.

### 26.1 Manufactured and Distributed by:

**OMINEDO PHARMACEUTICAL INDUSTRY CO., LTD.**  
574, Nenarigaki, Yamatotakada-city, Nara 635-0051, Japan

### 26.2 Distributed by:

**Kracie Pharmaceutical, Ltd.**

20-20, Kaigan 3-Chome, Minato-ku, Tokyo 108-8080, Japan